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http://dx.doi.org/10.1016/j.stemcr.2016.10.008SUMMARYEmbryonic stem cells (ESCs) are fast proliferating cells capable of differentiating into all somatic cell types. In somatic cells, it is well docu-
mented that p53 is rapidly activated upon DNA damage to arrest the cell cycle and induce apoptosis. In mouse ESCs, p53 can also be
functionally activated, but the precise biological consequences are not well characterized. Here, we demonstrated that doxorubicin treat-
ment initially led to cell-cycle arrest at G2/M in ESCs, followed by the occurrence ofmassive apoptosis. Neither p53nor its target gene p73
was required for G2/M arrest. Instead, p53 and p73 were fully responsible for apoptosis. p53 and p73 were also required for differentia-
tion-induced apoptosis in mouse ESCs. In addition, doxorubicin treatment induced the expression of retinoblastoma protein in a p53-
dependent manner. Therefore, both p53 and p73 are critical in apoptosis induced by DNA damage and differentiation.INTRODUCTION
Embryonic stem cells (ESCs) are self-renewing pluripotent
cells, derived from the inner cell mass of blastocyst (Smith,
2001). The transcriptional control of pluripotency is well
characterized. Master transcription factors, such as Pou5f1
(Oct4), Sox2, and Nanog, maintain pluripotency and sup-
press lineage-affiliated transcripts. Another distinct feature
of ESCs is their fast proliferation rate with a much trun-
cated G1 phase. Such characteristics impose a burden for
ESCs to maintain genome stability. ESCs are hyper-sensi-
tive to DNA damage, resulting in high levels of apoptosis
(Hong and Stambrook, 2004; Qin et al., 2007). The molec-
ular underpinnings are not well understood.
The molecular mechanisms that control ESC cell-cycle
progression and genome stability may differ from those
in somatic cells. For example, p53 is a well-known tumor
suppressor and frequently mutated in cancer (Freed-Pastor
and Prives, 2012; Isobe et al., 1986; Kruse and Gu, 2009).
The major function of p53 is to maintain genome stability.
In response to cellular stresses, p53 is stabilized and acti-
vated, resulting in cell-cycle arrest, apoptosis, or senescence
by directly trans-activating downstream target genes such
as p21, Mdm2, Noxa, and Puma (Vousden and Prives,
2009). However, the role of p53 in ESCs uponDNA damage
is controversial, with some studies showing p53-depen-
dent apoptosis while others show opposite results (Aladjem
et al., 1998; de Vries et al., 2002). In addition, the role of the
p53 protein family member, p73, is not clear in ESCs. The
Trp73 gene encodes twomajor isoforms, TAp73 andDNp73,
transcribed from alternative promoters (Sayan et al., 2010).Stem Cell Report
This is an open access article under the CTAp73 can induce cell death via trans-activation of target
genes (Irwin et al., 2000), whereas the amino-terminal
truncated DNp73 has an anti-apoptotic function (Naka-
gawa et al., 2002).
Retinoblastoma protein (RB) is a well-characterized tu-
mor suppressor that negatively regulates G1/S transition
in somatic cells. RB is highly expressed in ESCs but does
not seem to be functional in affecting cell-cycle progres-
sion, presumably due to its hyper-phosphorylation. How-
ever, ESCs require the RB protein family to initiate the
differentiation program (Conklin et al., 2012).
In this study, we show that doxorubicin induced dra-
matic G2/M cell-cycle arrest followed by massive apoptosis
in mouse ESCs. Interestingly, cell-cycle G2/M arrest was
not dependent on p53, p73, or RB. In contrast, both p53
and p73 proteins were required for doxorubicin-induced
apoptosis. In addition, knockdown of either p53 or p73
significantly reduced differentiation-induced apoptosis.
Notably, p53 also induced RB expression in ESCs likely
via suppression of RB-targeting miRNAs. Together, these
results suggest that p53 and p73 function to maintain
genome stability in ESCs by inducing apoptosis upon
DNA damage and differentiation.RESULTS
Doxorubicin Induces Cell-Cycle Arrest and Apoptosis
in Mouse Embryonic Stem Cells
In order to investigate the cellular response of mouse
ESCs to DNA damage, we treated R1 mouse ESCs withs j Vol. 7 j 1087–1098 j December 13, 2016 j ª 2016 The Authors. 1087
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
AB
D E
C
(legend on next page)
1088 Stem Cell Reports j Vol. 7 j 1087–1098 j December 13, 2016
doxorubicin. As expected, R1 cells cultured under self-
renewal conditions proliferated rapidly as demonstrated
by a high percentage of S-phase cells. Treatment of doxoru-
bicin for 12 hr induced G2/M cell-cycle arrest in a dose-
dependent manner. Apparently, doxorubicin at a final
concentration of 150 nM was effective to induce cell-cycle
arrest at G2/M (Figure 1A). Notably, there was little sub-G1
cell population under these conditions (Figure 1A, bottom
panel). To examine the effects of low-dose doxorubicin on
cell-cycle progression, we treated R1 cells with 50 nMdoxo-
rubicin for up to 48 hr. As shown in Figure 1B, G2/M frac-
tions of R1 cells were 47% at 12 hr, 62% at 24 hr, and
81% at 36 hr. At 48 hr, there was a significant sub-G1
population. Notably, cisplatin (CDDP) also induced G2/M
arrest and apoptosis in R1 mouse ESCs (Figure S1). Simi-
larly, doxorubicin also induced G2/M arrest and apoptosis
in another mouse ESC line, AB2.2 (Figure S2).
We then analyzed the expression of p53, p73, and RB
protein in mouse ESCs upon doxorubicin or CDDP. p53,
p73, and RB protein levels were significantly increased
upon treatment of doxorubicin (Figure 1C) or CDDP (Fig-
ure S1). Similarly, doxorubicin also induced p53, p73, and
RB protein levels in AB2.2 mouse ESCs (Figure S2).
In order to investigate the role of p53, p73, and RB in
doxorubicin-induced G2/M cell-cycle arrest, R1 cells stably
expressing shRNA constructs specific for p53 (sh-p53-1, sh-
p53-2) or p73 (sh-p73-1, sh-p73-2) (Johnson et al., 2007;
Kawamura et al., 2009), as well as control cells (sh-GFP),
were generated. As shown in Figure 1D, knockdown of
p53 or p73 did not alter the cell-cycle profiles upon doxoru-
bicin treatment, indicating that doxorubicin-induced G2/
M cell-cycle arrest is independent of p53 or p73. Similarly,
knockdown of RB had no significant effect on doxorubicin-
induced G2/M arrest (Figure 1E).
We then investigated protein(s) that might be respon-
sible for doxorubicin-induced G2/M arrest of R1 cells.Figure 1. Doxorubicin Induces G2/M Arrest of R1 Cells Independe
R1 cells were treated with doxorubicin (Dox) at the indicated concen
western blot analyses (C).
(A) Left: cell-cycle profiles. Right: percentages of cells in G1, S, and
experiments.
(B) R1 cells were treated with 50 nM doxorubicin for the indicated tim
experiments were performed. Representative histograms are shown.
(C) Western blot analysis of p53, p73, and RB protein levels after diff
served as a loading control.
(D) Stable R1 cells expressing sh-GFP, sh-p53-1, sh-p53-2, sh-p73-1, o
were then subjected to western blot analyses or FACS analyses. At lea
histograms and western blot data are shown.
(E) Stable R1 cells expressing sh-GFP or sh-RB were treated with 50
analyses or FACS analyses. At least three independent experiments we
shown.
See also Figures S1–S3.It has been reported that ionizing radiation induces
ATM-dependent G2/M arrest in human ESCs (Momcilovic
et al., 2009). We treated R1 cells with 50 nM doxorubicin
for either 12, 24, or 36 hr in the presence of KU55933, an
ATM inhibitor (Qi et al., 2016). Consistent with previous
reports (Hickson et al., 2004), inhibition of ATM reduced
the level of p53 comparable with that in control cells
(compare lane 5 with lane 1, Figure S3). However, inhibi-
tion of ATM did not alter G2/M arrest induced by doxoru-
bicin (Figure S3).
p53 and p73 Are Critical in Doxorubicin-Induced
Apoptosis in Mouse ESCs
We studied the time course of doxorubicin-induced
cell-cycle arrest and apoptosis. As shown in Figure 2A,
high-dose doxorubicin (250 nm) induced G2/M accumula-
tion in R1 mouse ESCs in a time-dependent fashion, and
reached a plateau at 12 hr after treatment, followed by
the occurrence of apoptosis at 20 hr, and increased sub-
stantially at 24 hr. Thus, G2/M cell-cycle arrest preceded
apoptosis. Western blot analyses showed that doxorubicin
significantly increased expression of p53, preceding the
increased expression of p73 and RB, and also cleaved cas-
pase-3 in R1 and AB2.2 ESCs (Figures 2B and S2).
To investigate whether p53 and p73 regulate apoptosis
in response to doxorubicin in ESCs, we generated ESC
lines stably expressing short hairpin RNA specific for
mouse p53 (sh-p53-1 and sh-p53-2), mouse p73 (sh-p73-
1 and sh-p73-2) (Johnson et al., 2007; Kawamura et al.,
2009), or GFP (sh-GFP) as a control. As shown in Fig-
ure 2C, knockdown of p53 completely abolished doxoru-
bicin-induced apoptosis, whereas knockdown of p73
significantly, but not completely, reduced doxorubicin-
induced apoptosis. Consistent with the fluorescence-
activated cell sorting (FACS) data, western blot analyses
confirmed that doxorubicin readily induced apoptosis, asntly of p53, p73, or RB
tration for 12 hr and were then subjected to FACS analyses (A) or
G2/M. Data are presented as means ± SE from three independent
e and then subjected to FACS analyses. At least three independent
erent doses of doxorubicin treatment for 12 hr in R1 cells. b-Actin
r sh-p73-2 were treated with 50 nM doxorubicin for 36 hr, and cells
st three independent experiments were performed. Representative
nM doxorubicin for 0, 12, or 24 hr and subjected to western blot
re performed. Representative histograms and western blot data are
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demonstrated by cleaved caspase-3 in control cells but
not cells with knockdown of p53. Notably, re-introduc-
tion of human DNp73a in p73 knockdown cells almost
completely inhibited doxorubicin-induced apoptosis (Fig-
ure 2D), suggesting that DNp73a functioned to inhibit
apoptosis in response to doxorubicin.
Mouse ESCs have been shown to exist as a multiple state
of pluripotency. Thus, we cultured R1mouse ESCs in 2i/LIF
conditions to induce cells to the naive state (Ying et al.,
2008). As shown in Figure S4, as expected, naive R1 mouse
ESCs exhibited a different morphology cell-cycle profile
with a high percentage of G1 phase and a clear increase
in the Nanog protein level and a decrease in c-MYC protein
levels (Silva et al., 2009; Ying et al., 2008). Doxorubicin
treatment of naive R1 mouse ESCs (sh-GFP) induced G2/
M arrest and apoptosis. Similar to that of R1 cells grown
in serum-containing media, effective knockdown of
p53, as demonstrated by western blot analyses, did not
affect doxorubicin-induced G2/M arrest, but it completely
abolished apoptosis; again, knockdown of p73 did not
affect doxorubicin-induced G2/M arrest but dramatically
reduced apoptosis. Thus, our data indicate that p53 induces
p73 expression, and both p53 and p73 play critical roles in
apoptosis of both primed and naive-state mouse ESCs in
response to doxorubicin.
p53 Upregulates p73 Transcription in Mouse ESCs in
Response to Doxorubicin
Post-translational modification of p53 is critical in the
regulation of p53 stability, cellular localization, and activ-
ity (Kruse andGu, 2009). Indeed, doxorubicin dramatically
induced p53 phosphorylation at Ser-18 (Figure 3A), amodi-
fication known to decrease the p53-MDM2 interaction,
which leads to p53 protein accumulation and increased
transcriptional activity (Chao et al., 2000). To demonstrate
that p53 trans-activation activity in mouse ESCs is upregu-
lated in response to doxorubicin, we performed real-time
qPCR analyses. As shown in Figure 3B, doxorubicin signif-Figure 2. High-Dose Doxorubicin Treatment Induces Apoptosis o
R1 cells were treated with 250 nM doxorubicin for the indicated tim
analyses (B).
(A) Left: cell-cycle profiles. Right: percentages of cells in G1, S, G2/M,
independent experiments.
(B) Western blot analysis of p53, p73, RB, and cleaved caspase-3 prote
b-Actin served as a loading control.
(C) Stable R1 cells expressing sh-GFP, sh-p53-1, sh-p53-2, sh-p73-1, o
points and subjected to western blot analyses or FACS analyses. At le
histograms and western blot data are shown.
(D) R1 sh-p73 cells with ectopic expression of humanDNp73a were tre
analyses or FACS analyses. At least three independent experiments we
shown.
Data presented are means ± SE calculated from three independent exicantly increased p21 and MDM2 mRNA levels but sig-
nificantly reduced Nanog mRNA levels, consistent with
a previous report that p53 negatively regulates Nanog
expression (Lin et al., 2005). Notably, both p73 mRNA
and protein levels were dramatically increased upon
doxorubicin treatment in R1 mouse ESCs but not in p53
knockdown R1 mouse ESCs (Figure 3C). We concluded
that doxorubicin upregulates p73 expression in a p53-
dependent manner in mouse ESCs.
p53 Upregulates RB Protein Expression in Mouse ESCs
in Response to Doxorubicin
Our aforementioned data demonstrated that both p53 and
RB protein levels were increased significantly in response to
doxorubicin (Figure 1B). We therefore examined whether
p53 plays a role in doxorubicin-induced upregulation of
RB expression. As shown in Figure 4A, again, in response
to doxorubicin, RB protein expression was significantly
increased in R1 mouse ESCs, but not in the cells with p53
knocked down. Real-time qPCR analyses showed that the
RB mRNA levels were comparable in control cells and sh-
p53-1 cells upon doxorubicin treatment (Figure 4B). These
data suggest that p53-mediated regulation of RB is most
likely at the post-transcriptional level.
It has been reported that miRNAs are potential regulators
of RB protein translation. We used three algorithms,
TargetScan, microRNA.org, and PicTar, to search for poten-
tial miRNA candidates that might regulate RB expression.
The top candidates were miR-17, miR-20a, miR-106a, and
miR-20b derived from the mir-17-92 gene and mir-106a-
363 gene cluster (Mendell, 2008). These four miRNAs
contain the same core sequence complementary to the 30
UTR of mouse RB mRNA (Figure 4C). We therefore hy-
pothesized that p53 likely suppresses expression of these
miRNAs that resulted in upregulation of RB expression.
To explore this possibility, we performed real-time qPCR
analyses to examine the expression of pri-miR-17-92 and
pri-miR-106a-363 in R1 sh-GFP and R1 sh-p53-1 cellsf R1 Cells in a p53-Dependent Manner
e. Cells were then subjected to FACS analyses (A) or western blot
and sub-G1. Data are presented as means ± SE calculated from three
in levels after 250 nM doxorubicin treatment at the indicated time.
r sh-p73-2 were treated with 250 nM doxorubicin at indicated time
ast three independent experiments were performed. Representative
ated with 50 nM doxorubicin for 36 hr and subjected to western blot
re performed. Representative histograms and western blot data are
periments. *p < 0.05; **p < 0.01. See also Figures S1 and S4.
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Figure 3. Doxorubicin Induces p73 Expression in R1 Cells in a p53-Dependent Manner
(A) R1 cells were treated with 250 nM doxorubicin for 6 or 12 hr. Western blot analyses for total p53 and phosphor-p53 (S18) were
performed. b-Actin served as a loading control.
(B) R1 cells were treated with or without 250 nM doxorubicin for 6 or 12 hr. Total RNA was isolated and the expression of p53 downstream
targets, p21, MDM2, and Nanog, were analyzed by qPCR. The changes in steady-state levels of mRNA (fold) were calculated using the –DDCt
method and normalized using b-actin as a control. The mean of three independent experiments in triplicate are presented. Error bars
represent SEM.
(C) R1 sh-GFP and R1 sh-p53-1 cells were treated with or without 250 nM doxorubicin for 12 hr and subjected to western blot analyses or
qPCR analyses, as indicated. The steady-state levels of mRNA changes (fold) were calculated using the –DDCt method and normalized using
b-actin as a control. The mean of three independent experiments in triplicate are presented. Error bars represent SEM.upon doxorubicin treatment. Interestingly, the expression
of pri-miR-17-92 and pri-miR-106a-363 was dramatically
decreased in sh-GFP cells followingDNAdamage. However,
the expression levels of these two miRNA clusters were
largely comparable with p53 knockdown. Thus, it seemed
that p53 likely upregulated RB expression via suppression
of RB-targeting miRNAs.
Differentiation-Induced Apoptosis of Mouse ESCs
It hasbeen shown thatwithdrawalofLIF inducesmouse ESC
differentiation and apoptosis (Duval et al., 2006). Mouse R1
ESCs cultured in the absence of LIF for 72 hr underwent
differentiation demonstrated by AP staining (Figure 5A).
We therefore examined the expressionofproteins associated
with pluripotency (Nanog, Oct4) and apoptosis (p53, p73,
and cleaved caspase-3). As shown in Figure 5B, LIF with-
drawal induced differentiation as indicated by downregula-1092 Stem Cell Reports j Vol. 7 j 1087–1098 j December 13, 2016tion of Oct4 and Nanog. Cleaved caspase-3, a marker of
apoptosis, also increased. Interestingly, while p53 protein
levels remained the same, in keeping with a recent report
that p53protein levels are unchangedduringdifferentiation
inhumanESCs (Setoguchi et al., 2016), the levels of p73, RB,
and cleaved caspase-3 were significantly increased (Figures
5B and S5). Similar observations were evident in AB2.2
mouse ESCs under similar experimental settings (Figure S5).
To investigate the role of p53 and/or p73 in differentia-
tion-induced apoptosis in mouse ESCs, we examined the
expression of apoptosis-associated PUMA and cleaved
caspase-3 in control cells (sh-GFP), with p53 knockdown
(sh-p53-1 or sh-p53-2), p73 knockdown (sh-p73-1, or
sh-p73-2), or with double knockdown of p53 and p73
(sh-p53-1 and sh-p73-1). As shown in Figure 5C, again,
upon LIF withdrawal, protein levels of p73, PUMA, and
cleaved caspase-3 were increased significantly, whereas
AC D
B
Figure 4. Doxorubicin Induces RB Protein Expression in R1 Cells in a p53-Dependent Manner
(A) R1 sh-GFP and R1 sh-p53-1 cells were treated with 50 nM doxorubicin for 12, 24, or 36 hr and were then subjected to western blot
analyses.
(B) R1 sh-GFP and R1 sh-p53-1 cells were treated with or without 250 nM doxorubicin for 12 hr. Relative mRNA levels of RB were determined
by qPCR. The steady-state levels of mRNA changes (fold) were calculated using the –DDCt method and normalized using b-actin as a
control. The mean of three independent experiments in triplicate are presented. Error bars represent SEM.
(C) Schematic representation of the 30 UTR sequence of mouse RB1 indicating the putative miRNA-binding sites (shown in bold). Four
putative microRNAs are shown.
(D) R1 sh-GFP and R1 sh-p53-1 cells were treated with or without 250 nM doxorubicin for 12 hr. Expression levels of pri-miR-17-92 and
pri-miR-106a-363 were analyzed by qPCR using EvaGreen and normalized to b-actin. The mean of three independent experiments in
triplicate are presented. Error bars represent SEM.the p53 protein level did not change. Unlike doxorubicin-
induced p73 upregulation, which is dependent on p53,
LIF-withdrawal-mediated upregulation of p73 protein was
p53 independent. Furthermore, single knockdown of p53
or p73, alone, led to dramatically reduced expression of
PUMAandcleaved caspase-3,whereas simultaneous knock-
down of p53 and p73 completely abolished apoptosis,
which was further supported by the data from the FACS
analyses (Figure 5D). Together, these results indicate that
p53 or p73 possesses the overlapping function in promot-
ing differentiation-associated apoptosis.DISCUSSION
ESCs have the ability to proliferate indefinitely in vitro.
Underlying this remarkable ability are inextricably linkedmolecular regulatory networks such as the c-MYC and
PI3K signaling pathways. However, it is not entirely clear
how ESCs maintain their genome stability under stressed
conditions such as DNA damage.
In this study, we investigated the role of p53, which plays
a key role in guarding genome stability, in ESCs. Consistent
with a previous report that p53 is important for Adriamycin
(a trade name of doxorubicin)-induced apoptosis in mouse
ESCs (Li et al., 2015), we found that doxorubicin or CDDP
robustly activates p53/p73/RB, and cells were arrested at
G2/M followed by massive apoptosis in mouse ESCs.
Notably, chemical inhibition of CDK1 in ESCs can trigger
DNA damage, leading to G2/M arrest and subsequent
apoptosis (Huskey et al., 2015). This observation is consis-
tent with our results that G2/M arrest precedes apoptosis.
We demonstrate that both p53 and p73 play a pivotal
role in promoting apoptosis induced either by DNAStem Cell Reports j Vol. 7 j 1087–1098 j December 13, 2016 1093
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damage or by differentiation, whereas they are dispensable
in cell-cycle G2M arrest in mouse ESCs in response to DNA
damage.
Our study showed that neither p53 nor p73 nor RB is
responsible for G2/M arrest induced by DNA damage.
Although we do not know the exact mechanism for doxo-
rubicin/CDDP-induced G2M arrest, we show that inhibi-
tion of ATM did not affect doxorubicin-induced G2/M
arrest, suggesting that ATM signaling is dispensable for
this process. Since CDK1 is a well-established master regu-
lator of G2/M, it is possible that critical cell-cycle regula-
tors, such as CDK1 or CDC25, also play a critical role in
G2/M arrest in response to doxorubicin/CDDP treatment.
Since the cell cycle in ESCs is unique, it seems that ESCs
may use a novel checkpoint pathway(s) to monitor DNA
damage to control cell-cycle progression in maintaining
its genome integrity. It will be of interest to identify this
novel pathway in future studies.
ESCs can differentiate into a variety of somatic cells
in vitro, providing an excellent system to dissect molecular
mechanisms under various cellular contexts. We show that
both TAp73 and DNp73, two isoforms transcribed from the
Trp73 gene using alternative transcription start sites, are
upregulated in a p53-dependent manner upon doxoru-
bicin treatment in ESCs, in keeping with a report that
p53 can bind the promoter of DNp73 (Murray-Zmijewski
et al., 2006). Previous studies have shown that TAp73
promotes apoptosis, whereas DNp73 functions as a domi-
nant-negative inhibitor of p53 and inhibits TAp73 tran-
scriptional activity to attenuate apoptosis. In this study,
we found that p53-induced TAp73 is largely responsible
for doxorubicin-induced apoptosis in mouse ESCs, while
ectopic expression of DNp73 suppresses this process. Strik-
ingly, we found that induction of p73 upon ESC differenti-
ation is independent of p53. Thus, the molecular pathway
in the regulation of p73 is different upon DNA damage or
upon differentiation in mouse ESCs. Consistently, knock-
down of p53 alone (and thus reduction of p73 expression)
is sufficient to block doxorubicin-induced apoptosis, while
simultaneous knockdown of both p53 and p73 completely
abolishes differentiation-induced apoptosis. It is plausible
that regulation of p73 during differentiation using a p53-
independent pathway may be because p73 functions inFigure 5. Differentiation-Induced Apoptosis of R1 Cells
(A) R1 cells were cultured in the absence of LIF for 72 hr followed by A
microscopy.
(B) R1 cells were cultured in the absence of LIF for 72 or 96 hr. Cells
loading control.
(C and D) R1 sh-GFP, R1 sh-p53-1, R1 sh-p53-2, R1 sh-p73-1, R1 sh-p7
LIF for 72 or 96 hr. Cells were subjected to western blot (C) or FACS an
Representative histograms and western blot data are shown.
See also Figure S5.developmental processes such as neurogenesis. It will be
of interest to investigate how p73 is regulated during differ-
entiation, and how this molecular pathway overrides the
regulation by p53.
Surprisingly, we found that activation of p53 led to a
significant increase in RB protein expression in response
to DNA damage in mouse ESCs, likely via p53-dependent
suppression ofmiR-17-92 andmiR-106a-363 cluster expres-
sion, which target to and inhibit RB expression. Previous
studies have shown that RB does not seem to be functional
in affecting cell-cycle progression in ESCs, presumably due
to its hyper-phosphorylation, but RB is important for
proper differentiation (Conklin et al., 2012). Thus, we sus-
pect that RB induction by p53 sets up a cellular environ-
ment favorable to differentiation. More studies are needed
to dissect the underlying mechanisms.
In summary, we demonstrate that p53 and p73 are major
players in the regulation of apoptosis in mouse ESCs upon
DNA damage or differentiation, indicating that p53 safe-
guards ESC genome stability by eliminating damaged cells.
We also show that ESCs are an excellent experimental sys-
tem to discover novelmolecularmechanisms regarding the
regulation of p73 and RB. We anticipate that understand-
ing the difference and similarities between ESCs and cancer
cells will be of value to regenerativemedicine and to cancer
biology.EXPERIMENTAL PROCEDURES
Cell Culture and Drug Treatment
R1 mouse ESCs and AB2.2 mouse ESCs were cultured in DMEM
(Hyclone), 15% embryonic stem screened fetal bovine serum (Hy-
clone), 1 mM L-glutamine, 1% non-essential amino acids, 0.1 mM
b-mercaptoethanol, 1% penicillin G/streptomycin sulfate (all from
Invitrogen) and 1,000 U/ml LIF (Millipore) at 37C in a humidified
5% CO2 incubator. Cells cultured in 2i/LIF were maintained in N2/
B27media, consisting of 50%DMEM/F12 (1:1) and 50%Neurobasal
plus 0.53 N-2 supplement, 0.53 B-27 supplement, 13 penicillin/
streptomycin, 13 Glutamax and 13 non-essential amino acids
(NEAA) (all from Gibco), and 13 b-Me (Millipore) supplemented
with 1 mM MEK inhibitor PD0325901 (Gene Operation), 3 mM
GSK3 inhibitor CHIR99021 (Gene Operation), and 1,000 U/ml
LIF(Millipore). Doxorubicin andCDDPwere purchased from Sigma.P staining. Representative images were captured by phase-contrast
were then subjected to western blot analyses. b-Actin served as a
3-2, and R1 sh-p53-1/sh-p73-1 cells were cultured in the absence of
alyses (D). At least three independent experiments were performed.
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Western Blot Analysis
Cells were collected, washed with PBS, and re-suspended in EBC
250 lysis buffer (50 mM Tris–HCl [pH 8.0], 250 mM NaCl, 0.5%
Nonidet P-40, 50 mM NaF, and 0.5 mM Na3VO4, 0.2 mM PMSF,
2 mg/mL leupeptin, 2 mg/mL aprotinin). Protein concentration was
determined using the Bio-Rad protein assay reagent (Bio-Rad). An
equal amount of protein (about 40–60 mg total protein)was loaded,
separated on 10%SDS-PAGE, transferred to polyvinylidene difluor-
idemembrane (Bio-Rad), andhybridized to an appropriate primary
antibody and horseradish-peroxidase-conjugated secondary anti-
body for subsequent detection by ECL (Millipore). Monoclonal
antibody 1C12 specific for p53 (Cell Signaling Technology) was
used at a dilution of 1:1000, and phospho-p53 polyclonal antibody
(#9284S, Cell Signaling Technology) was used at 1:500. Rabbit
monoclonal antibody specific for p73 (#1636-1, Epitomics) and
mouse monoclonal antibody specific for RB (#554136, BD) or
for Oct4 (Zen BioScience) were used at 1:1,000. Polyclonal anti-
body specific for Nanog (A300-397, Bethyl) was used at a dilu-
tion of 1:3,000. Polyclonal antibodies for caspase-3 (#9661,
Cell Signaling Technology) or PUMA (#7467, Cell Signaling
Technology) were used at 1:1,000. Goat polyclonal antibody
specific for actin (C-11, Santa Cruz Biotechnology) was used at
1:500.Constructs
The shRNA constructs specific for p53, p73, and RBwere generated
as described (Blais et al., 2007; Johnson et al., 2007; Kawamura
et al., 2009). pLVX-shRNA1 vector was obtained from Clontech.
sh-p53-1 and sh-p53-2 against p53, sh-p73-1 and sh-p73-2 against
pan p73, sh-RB against RB, or sh-GFP control were inserted into
pLVX-shRNA1 and confirmed by DNA sequencing.
The target sequences of all these shRNAs are listed as follows:
sh-p53-1: 50-GTACATGTGTAATAGCTCC-30
sh-p53-2: 50-CCGACCTATCCTTACCATCAT-30
sh-p73-1: 50-GGGACTTCAATGAAGGACA-30
sh-p73-2: 50-TGAGATCTTGATGAAAGTCAA-30
sh-RB: 50-GCATATCTCCGACTAAATA-30
sh-GFP: 50-GAAGCAGCACGACTTCTTC-30
For overexpression experiments, full-length human DNp73a
cDNA was sub-cloned into lentiviral vector pLVX-hPGK-puro,
derived from pLVX-IRES ZsGreen1, followed by DNA sequence
confirmation.Lentiviral Infection
HEK293T cells were transfected with overexpression or shRNA
constructs (and their vector controls) along with pSPAX2 and
pMD2.G lentiviral packaging plasmids using lipofectamine 2000.
At 48 hr after transfection, the media were collected, and cells
were refed with growth media for another 24 hr. The combined
media were filtered through a 0.45 mm filter to remove debris.
The lentiviral particles were then concentrated by ultra-centrifuga-
tion (20,000 rpm, 2.5 hr at 4C), re-suspended in fresh mouse ESC
medium at 4C and put on ice at least for 4 hr, and then supple-
mented with polybrene (10 mg/mL) and used to infect cells.
Forty-eight hours after infection, the cells were selected in growth
medium supplemented with puromycin (2 mg/mL) for 48 hr.1096 Stem Cell Reports j Vol. 7 j 1087–1098 j December 13, 2016RNA Isolation and PCR Assays
Total RNA was isolated using Trizol reagent (Invitrogen) according
to the manufacture’s protocol. cDNA was created by using total
RNA as template in the 20 mL cDNA synthesis reaction mixture
containing random primers and reverse transcriptase (SuperScript
II; Invitrogen) at 42C for 1 hr, followed by 15min of denaturation
at 70C and then quick cooling. qPCR was performed in a CFX96
Real-time PCR system (Bio-Rad) using a SoFast EvaGreen Supermix
(Bio-Rad). The reactions were incubated in 96-well plates for
10 min, followed by 40 cycles of 95C for 15 s, 60C for 30 s.
b-Actin or GAPDHwas used as an endogenous control for normal-
ization. Primer sequences are follows:
p21 Fwd, CGAGAACGGTGGAACTTTGACTTC
p21 Rev, AGAGTGCAAGACAGCGACAAGG
MDM2 Fwd, TGAGGAGGACAGCGAGGAGAAG
MDM2 Rev, CCAGTCTTGCCGTGAACAATGC
Nanog Fwd, AGTACCTCAGCCTCCAGCAGATG
Nanog Rev, GCTTCCAGATGCGTTCACCAGAT
TAp73 Fwd, GCACCTACTTTGACCTCCCC
TAp73 Rev, GCACTGCTGAGCAAATTGAAC
DNp73 Fwd, ATGCTTTACGTCGGTGACCC
DNp73 Rev, GCACTGCTGAGCAAATTGAAC
RB Fwd, ACCTTGAACCTGCTTGTCCTCT
RB Rev, GGCTGAGGCTGCTTGTGTCT
Pri-miR-17-92 cluster Fwd, CAAAGTGCTTACAGTGCAGGTAG
Pri-miR-17-92 cluster Rev, TATCTGCACTAGATGCACCTTA
Pri-miR-106a-363 cluster Fwd, GCCATCTGTGCGGTATGTGAAG
Pri-miR-106a-363 cluster Rev, GCCACTCGGAAGGTCTCTATGT
b-actin Fwd, TCACTATTGGCAACGAGCGGTTC
b-actin Rev, GCACTGTGTTGGCATAGAGGTCTT
GAPDH Fwd, TGTGTCCGTCGTGGATCTGA
GAPDH Rev, CCTGCTTCACCACCTTCTTGAFACS Analyses
Cells were trypsinized, washed with cold PBS, and fixed in 70%
ethanol at 4C overnight. Cells (1 3 106) were stained with
50 mg/mL propidium iodide supplemented with 80 mg/mL RNase
A at room temperature in the dark for 1 hr. Cells were then sub-
jected to FACS analysis by FACScan flow cytometer (Becton Dick-
son). Data were analyzed using the Cell Quest program.
Procedure of Mouse ESC Differentiation
R1 cells or AB2.2 cells were plated at low cell density (13 105 cells/
well in a six-well plate) in mouse ESC medium containing LIF
(1,000 U/ml). Twelve hours after seeding, cells were washed once
with PBS at room temperature and fed with mouse ESC medium
supplemented with or without mLIF. The medium was changed
every 24 hr, and cells were collected at an indicated time (3 or
4 days).
Alkaline Phosphatase Staining Assay
Cells were washed once with PBS and fixed in 3.7% formalde-
hyde for 5 min at room temperature. Cells were then incubated
with AP staining buffer (FRV-Alkaline solution/sodium nitrite
solution/naphthol AS-BI alkaline solution; Sigma) at room
temperature for 10–30 min. Images of the stained cells were
captured with a Nikon (ECLIPSE Ti-U) reverse phase-contrast
microscope.
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